



Introducing SYMPHONY: A clinical study investigating BLU-945 in EGFR mutation-positive metastatic non-small cell lung cancer (mNSCLC)

BLU-945 is an investigational compound undergoing research; its safety and effectiveness in EGFR mutation-positive mNSCLC have not been demonstrated and it has not been approved by the FDA or any regulatory authority




What is EGFR mutation-positive metastatic NSCLC?



Lung cancer is the uncontrolled growth of cancerous cells within the lungs



Third most common cancer in the US¹



Approximately 85% of all lung cancers are NSCLC²



EGFR, or epidermal growth factor receptor, is a protein that is present in everyone's cells. When the EGFR protein is mutated or changed, this causes cells to divide rapidly and form cancerous tumors. There are different types of EGFR mutations. **EGFR inhibitors** may help shrink tumors, but sometimes these drugs stop working if another EGFR mutation develops.



What is BLU-945? BLU-945 is an investigational selective EGFR inhibitor which works by targeting tumors with specific EGFR mutations (*T790M* and *C797S*). **BLU-945** is taken orally. Your study doctor will tell you how often and how to take your study drug.



If you have **NSCLC**, it is important to have a conversation with your doctor about comprehensive biomarker testing to help them understand what is driving your cancer and to find the best treatment for you.

Always talk to your healthcare provider if you think you may have NSCLC

What is SYMPHONY?



SYMPHONY is a global **Phase 1 and 2**, open-label, first-in-human study that will measure the safety, tolerability, processing, and effectiveness (anticancer activity) of **BLU-945**

PHASE 1
currently enrolling

PHASE 2
not yet enrolling



EGFR mutation-positive mNSCLC

- Participants will be given different doses of **BLU-945** to help identify the dose for the **Phase 2** study

- Oral dose determined from **Phase 1**
- Participants whose tumors have **specific EGFR mutations**:



T790M and *C797S*



T790M only



C797S only

Study measures



The **SYMPHONY** study measures include, but are not limited to:



Safety

- To understand the possible side effects of **BLU-945**



Processing

- To understand how your body processes **BLU-945** and the effect of **BLU-945** on the body



Effectiveness

- Tumor shrinkage or disappearance with study treatment
- Length of time that a tumor continues to respond (no growing or spreading) to treatment

Key eligibility criteria



You may be eligible to take part if you:



Are 18 years old or older



Have a diagnosis of mNSCLC



Have an EGFR mutation found by your doctor with a tumor biopsy or a blood test



Received prior treatment with one or more EGFR-targeted tyrosine kinase inhibitor (TKI)



Have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2

- Other eligibility criteria may apply**; these will be assessed during screening visits with a study doctor at clinical study sites
- A study doctor will speak with you about the **SYMPHONY** study and you will need to sign an informed consent form before your participation

Resources



[For more information about SYMPHONY >](#)



[To connect to clinical trial sites >](#)



[To learn more about mNSCLC >](#)